Improving radiotherapy of squamous cell carcinoma of the head and neck (HNSCC) through a continuous process of biological based clinical trials − a 40-year experience from the Danish Head and Neck Cancer Group − DAHANCA

The most common histology of non-thyroid head and neck cancer is squamous cell carcinoma. Common risk factors for head and neck malignancies include tobacco and alcohol abuse and viruses, including Epstein-Barr Virus (EBV) and Human Papillomavirus (HPV). Early stage disease is often treated with surgery or radiation therapy alone, while more advanced disease often requires a multi-modality approach including systemic chemotherapy, radiation, and surgical resection. In the curative setting, current clinical trials are evaluating the de-escalation of therapy in HPV-releated head and neck cancer. In the metastatic setting, clinical trials have focused on using immunotherapy agents to improve outcomes. This review chapter will discuss the etiology and common presentations of head and neck cancer, and also analyze recent advancements in the treatment of the disease. Key words: chemoradiation, head and neck cancer, human papillomavirus, immunotherapy, oropharynx, squamous cell carcinoma, treatment deescalation

Download Full-text

Head and Neck Cancer

10.2310/im.1248 ◽

2018 ◽

Author(s):

Everett E Vokes ◽

Kevin C. Wood

Keyword(s):

Squamous Cell Carcinoma ◽

Clinical Trials ◽

Head And Neck Cancer ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Neck Cancer ◽

Squamous Cell ◽

Early Stage Disease ◽

Metastatic Setting

The most common histology of non-thyroid head and neck cancer is squamous cell carcinoma. Common risk factors for head and neck malignancies include tobacco and alcohol abuse and viruses, including Epstein-Barr Virus (EBV) and Human Papillomavirus (HPV). Early stage disease is often treated with surgery or radiation therapy alone, while more advanced disease often requires a multi-modality approach including systemic chemotherapy, radiation, and surgical resection. In the curative setting, current clinical trials are evaluating the de-escalation of therapy in HPV-releated head and neck cancer. In the metastatic setting, clinical trials have focused on using immunotherapy agents to improve outcomes. This review chapter will discuss the etiology and common presentations of head and neck cancer, and also analyze recent advancements in the treatment of the disease. Key words: chemoradiation, head and neck cancer, human papillomavirus, immunotherapy, oropharynx, squamous cell carcinoma, treatment deescalation

Download Full-text

Subglottic squamous cell carcinoma in Denmark 1971–2015 – a national population-based cohort study from DAHANCA, the Danish Head and Neck Cancer group

Acta Oncologica ◽

10.1080/0284186x.2019.1645355 ◽

2019 ◽

Vol 58 (10) ◽

pp. 1509-1513 ◽

Cited By ~ 1

Author(s):

Louise Hill-Madsen ◽

Claus A. Kristensen ◽

Elo Andersen ◽

Jørgen Johansen ◽

Lisbeth J. Andersen ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cohort Study ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Neck Cancer ◽

Squamous Cell ◽

Population Based ◽

National Population ◽

Cancer Group

Download Full-text

Incidence of and survival after glottic squamous cell carcinoma in Denmark from 1971 to 2011—A report from the Danish Head and Neck Cancer Group

European Journal of Cancer ◽

10.1016/j.ejca.2016.01.020 ◽

2016 ◽

Vol 59 ◽

pp. 46-56 ◽

Cited By ~ 7

Author(s):

Nina Munk Lyhne ◽

Jørgen Johansen ◽

Claus Andrup Kristensen ◽

Elo Andersen ◽

Hanne Primdahl ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Head And Neck Cancer ◽

Cell Carcinoma ◽

Head And Neck ◽

Neck Cancer ◽

Squamous Cell ◽

Cancer Group

Download Full-text

Progress of molecular targeted therapy for head and neck cancer in clinical aspects

Molecular Biomedicine ◽

10.1186/s43556-021-00032-5 ◽

2021 ◽

Vol 2 (1) ◽

Author(s):

Kenji Nakano

Keyword(s):

Squamous Cell Carcinoma ◽

Clinical Trials ◽

Head And Neck Cancer ◽

Targeted Therapy ◽

Cell Carcinoma ◽

Head And Neck ◽

Cancer Patients ◽

Neck Cancer ◽

Squamous Cell ◽

Molecular Targeted Therapy

AbstractSince the body’s head and neck area affects many functions such as breathing, swallowing, and speaking, systemic treatments to head and neck cancer patients are important not only for survival but also for preserving functions and quality of life. With the progress that has been made in molecular targeted therapy, anti-EGFR antibody (cetuximab) and immune checkpoint inhibitors (nivolumab, pembrolizumab) have provided survival benefits to head and neck cancer patients and are approved for clinical practice. Clinical trials incorporating these new drugs for patients with locally advanced head/neck cancers are underway. However, the existing clinical evidence regarding molecular targeted drugs for head and neck cancers is based mostly on clinical trials allocated to squamous cell carcinoma patients. New targeted therapies for non-squamous cell carcinoma patients were recently reported, e.g., tyrosine kinase inhibitors for the treatment of thyroid cancers and HER2-targeted therapy for salivary gland cancers. With the goal of improving local control, molecular targeted treatment strategies as salvage local therapy are being investigated, including boron neutron capture therapy (BNCT) and near-infrared photoimmunotherapy (NIR-PIT). Herein the history and landscape of molecular targeted therapy for head and neck cancers are summarized and reviewed.

Download Full-text